haematology
Blood cancers

“Ibrutinib is the efficacy standard”: targeted therapy pips chemo in CLL


Ibrutinib, alone or with rituximab, outperforms bendamustine and rituximab in older patients with previously untreated chronic lymphocytic leukaemia (CLL), according to findings presented at ASH 2018. In study released at the 2018 American Society of Hematology (ASH) Annual Meeting in San...

Ibrutinib, alone or with rituximab, outperforms bendamustine and rituximab in older patients with previously untreated chronic lymphocytic leukaemia (CLL), according...

Read more